FDA panel unanimously endorses Glaxo's Shingrix as $1B market duel nears

13th September 2017 Uncategorised 0

Marking a big step in its march toward potential approval, GlaxoSmithKline’s shingles vaccine candidate Shingrix won the support of an FDA expert panel Wednesday. The shot, slated to be a blockbuster, now heads to the FDA for an October action date.

More: FDA panel unanimously endorses Glaxo's Shingrix as B market duel nears
Source: fierce